ITGB1 and nasopharyngeal carcinoma: ITGB1 was verified to promote various chemo-therapeutic resistance in cancer types, including tamoxifen resistance and epirubicin resistance in breast cancer cells, docetaxel resistance in esophageal squamous cell carcinoma, bevacizumab resistance in glioblastoma, osimertinib resistance inhibitor resistance in non-small cell lung cancer, and paclitaxel resistance in nasopharyngeal cancer [78–84].